Several adverse health outcomes are associated with AD, such as atopic and allergic conditions, immune mediated conditions, and more.

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

Work-time, rather than leisure-time or nonworkday, activity behavior seems to be associated with 24-hour ambulatory blood pressure.